Method for the Treatment of Attention Deficit/Hyperactivity Disorder (ADHD) Using Sodium Hydrogen Exchange Inhibitors

The Problem:

According to the Center for Disease Control, nearly 10% of children in the United States will be diagnosed with ADHD at some point. In 2007, there were 2.7 million children with an active diagnosis receiving medication to treat ADHD. Currently, the primary medications used to treat ADHD are central nervous system stimulants, with notable adverse side effects including nausea, trouble sleeping and nervousness. Furthermore, these stimulant based treatments are not always effective in treating ADHD and in some cases can be abused. SUNY Upstate’s new treatment seeks to address the very large market need for a non-stimulant ADHD treatment.

Upstate’s Solution:

Upstate’s solution to this problem is to focus on treating ADHD through the sodium/hydrogen exchange pathway (NHE). Our research on two strains of mice indicates that inhibition of NHE 9 (SLC9A9) would treat ADHD symptoms in a similar fashion to clonidine. Currently, there are a number of NHE inhibitors on the market that are typically used as diuretics, anti-hypertensive agents, and for the prevention of cardiac or neural ischemia. Inhibition of NHE 9 should serve as an effective, non-stimulant, alternative treatment for ADHD.

 

Benefits:

•Non-stimulant class of drugs
• NHE inhibitors are already FDA approved
Patent Information:
Technology/Start-up ID: